Literature DB >> 11292612

Insulin-like growth factor I and insulin-like growth factor binding protein 5 in Crohn's disease.

E M Zimmermann1, L Li, Y T Hou, N K Mohapatra, J B Pucilowska.   

Abstract

Insulin-like growth factor (IGF)-I and its binding protein IGF binding protein 5 (IGFBP-5) were highly expressed in inflamed and fibrotic intestine in experimental Crohn's disease. IGF-I induced proliferation and increased collagen synthesis by smooth muscle cells and fibroblasts/myofibroblasts in vitro. Here we studied IGF-I and IGFBP-5 in Crohn's disease tissue. Tissue was collected from patients undergoing intestinal resection for Crohn's disease. IGF-I and IGFBP-5 mRNAs were quantitated by RNase protection assay and Northern blot analysis, respectively. In situ hybridization was performed to localize mRNA expression, and Western immunoblot was performed to quantitate protein expression. IGF-I and IGFBP-5 mRNAs were increased in inflamed/fibrotic intestine compared with normal-appearing intestine. IGF-I mRNA was expressed in multiple cell types in the lamina propria and fibroblast-like cells of the submucosa and muscularis externa. IGFBP-5 mRNA was highly expressed in smooth muscle of the muscularis mucosae and muscularis externa as well as fibroblast-like cells throughout the bowel wall. Tissue IGFBP-5 protein correlated with collagen type I (r = 0.82). These findings are consistent with a mechanism whereby IGF-I acts on smooth muscle and fibroblasts/myofibroblasts to increase collagen synthesis and cellular proliferation; its effects may be modulated by locally expressed IGFBP-5.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292612     DOI: 10.1152/ajpgi.2001.280.5.G1022

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  22 in total

1.  Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis.

Authors:  Robert Barrett; Xiaolan Zhang; Hon Wai Koon; Michelle Vu; Jyh-Yau Chang; Nicole Yeager; Mary Ann Nguyen; Kathrin S Michelsen; Dror Berel; Charalabos Pothoulakis; Stephan R Targan; David Q Shih
Journal:  Am J Pathol       Date:  2011-12-02       Impact factor: 4.307

2.  Amelioration of excess collagen IαI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/-) mice.

Authors:  Sunila Mahavadi; Robert S Flynn; John R Grider; Li-Ya Qiao; Karnam S Murthy; Krystina B Hazelgrove; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2010-08-18       Impact factor: 5.325

3.  Increased IGF-IEc expression and mechano-growth factor production in intestinal muscle of fibrostenotic Crohn's disease and smooth muscle hypertrophy.

Authors:  Chao Li; Kent Vu; Krystina Hazelgrove; John F Kuemmerle
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-01       Impact factor: 4.052

4.  Altered expression of type I insulin-like growth factor receptor in Crohn's disease.

Authors:  F El Yafi; R Winkler; P Delvenne; N Boussif; J Belaiche; E Louis
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

5.  Endogenous IGF-I and alphaVbeta3 integrin ligands regulate increased smooth muscle hyperplasia in stricturing Crohn's disease.

Authors:  Robert S Flynn; Karnam S Murthy; John R Grider; John M Kellum; John F Kuemmerle
Journal:  Gastroenterology       Date:  2009-09-12       Impact factor: 22.682

6.  Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease.

Authors:  Kinan Rahal; Phyllissa Schmiedlin-Ren; Jeremy Adler; Muhammad Dhanani; Victoria Sultani; Ahren C Rittershaus; Laura Reingold; Ji Zhu; Barbara J McKenna; Gregory M Christman; Ellen M Zimmermann
Journal:  Inflamm Bowel Dis       Date:  2011-08-29       Impact factor: 5.325

Review 7.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

8.  Anti-TNFα alters the natural history of experimental Crohn's disease in rats when begun early, but not late, in disease.

Authors:  Phyllissa Schmiedlin-Ren; Laura J Reingold; Christopher S Broxson; Ahren C Rittershaus; Josh S Brudi; Jeremy Adler; Scott R Owens; Ellen M Zimmermann
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-25       Impact factor: 4.052

9.  Endogenous IGF-I and alpha v beta3 integrin ligands regulate increased smooth muscle growth in TNBS-induced colitis.

Authors:  Krystina B Hazelgrove; Robert S Flynn; Li-Ya Qiao; John R Grider; John F Kuemmerle
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-09       Impact factor: 4.052

10.  TGF-beta1 and IGF-1 and anastomotic recurrence of Crohn's disease after ileo-colonic resection.

Authors:  Marco Scarpa; Marina Bortolami; Susan L Morgan; Andromachi Kotsafti; Cesare Ruffolo; Renata D'Incà; Eugenia Bertin; Lino Polese; Davide F D'Amico; Giacomo C Sturniolo; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2008-08-13       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.